DRREDDY Share Price, Analysis & Fundamentals

Dr Reddy's faces significant fundamental headwinds with sharp QoQ and YoY declines in revenue and profit, while technicals show weak momentum and a neutral trend, indicating pressure persists.

The stock's technical indicators suggest a neutral trend regime and weak momentum, with the price trading below key moving averages and a bearish MACD signal. Short-term returns have been negative, with a 1-month return of -2.74%, indicating some downward pressure.
Recent quarterly results reveal a significant downturn in the company's financial performance, with revenue declining by -13.79% QoQ and -11.515% YoY. This sharp drop in revenue is accompanied by a substantial decrease in net profit, which fell by -81.429% QoQ and -86.074% YoY, highlighting considerable profitability challenges.
Despite the weak financial performance, analysts maintain a mixed outlook. While there's a notable portion of 'Buy' and 'Strong Buy' ratings (47.37%), an equally significant number of analysts recommend 'Sell' or 'Strong Sell' (39.47%), indicating a divergence in expert opinion on the stock's future prospects.
Institutional investors hold a substantial 51.86% stake in the company, with a slight increase in Domestic Institutional Investor (DII) holdings and a decrease in Foreign Institutional Investor (FII) positions. This institutional interest, coupled with a marginal 0.01% decrease in promoter holding, suggests a dynamic ownership landscape.
The company has been active with recent announcements, including the allotment of ESOP/ESPS on June 5, 2026, and prior intimations about analyst and investor meets. A Form 20-F filing with the SEC on May 30, 2026, for the fiscal year ended March 31, 2026, also provides recent corporate disclosures.

The stock has experienced negative short-term returns, with a 1-month return of -2.74% and a 3-month return of -0.87%.
The trend regime is neutral, indicated by a trend alignment score of -1 and the price being below the 9-day and 21-day EMAs.
Momentum is weak, with an RSI of 44.95 and a bearish MACD signal.
Volatility is moderate, with the price positioned at 32.07% of the Bollinger Band width and an annualized volatility of 19.28%.
The stock is trading 5.88% below its 52-week high and is currently in a drawdown of -5.88%.

The stock exhibits a neutral trend and weak momentum, with short-term returns being negative. It is currently trading below key EMAs and shows a bearish MACD signal. Volatility remains moderate, and the stock is positioned below its 52-week high, indicating some downward pressure. Volume conviction is not strongly indicated in the provided data.

The company reported revenue of ₹7,546 Cr in the latest quarter (Mar 2026).
Revenue experienced a QoQ decline of -13.79% and a YoY decline of -11.515%.
Net profit saw a significant QoQ decrease of -81.429% and a YoY decrease of -86.074%.
Profit before tax decreased by -87.038% QoQ and -90.025% YoY.

The company announced the allotment of ESOP/ESPS on June 5, 2026. Prior to this, it intimated about analyst and investor meets scheduled for June 3 and June 1, 2026. Additionally, a Form 20-F for the fiscal year ended March 31, 2026, was filed with the SEC on May 30, 2026.